Transaction DateRecipientSharesTypePriceValue
6th November 2020Kevin M Farr5,000Open or private purchase$4.43$22,150.00
1st October 2020Kevin M Farr310.72Grant/award etc.$94.54$29,375.47
1st July 2020Kevin M Farr276.37Grant/award etc.$90.91$25,124.80
19th May 2020Robert N Fried1,000Open or private purchase$4.69$4,690.00
30th April 2020Kevin M Farr1,833Grant/award etc.$70.93$130,014.69
1st April 2020Kevin M Farr636.93Grant/award etc.$46.12$29,375.21
2nd January 2020Kevin M Farr285.11Grant/award etc.$103.03$29,374.88
14th November 2019Robert N Fried10,000Open or private purchase$3.09$30,900.00
1st October 2019Kevin M Farr335.79Grant/award etc.$87.48$29,374.91
23rd August 2019Robert N Fried2,500Open or private purchase$4.03$10,075.00
Chroma Dex Corporation
Chroma Dex Corporation logo

Chromadex Corp. engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAgen to improve health by safely raising NAD levels. The Analytical reference standards and services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries.

Ticker: CDXC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1386570
Employees: 100
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags